Stock Price
880.40
Daily Change
2.00 0.23%
Monthly
20.64%
Yearly
11.11%
Q4 Forecast
859.60

EPS Reference Time Actual Consensus Previous
2026-10-22 FY2026Q3 6.97 6.14 4.48
2026-07-23 FY2026Q2 6.44 5.41 3.27
2026-05-07 FY2026Q1 4.69 4.7 2.29
2026-02-26 FY2025Q4 6.80 5.14 11.32
2025-10-30 FY2025Q3 4.48 3.89 1.28



Peers Price Chg Day Year Date
AstraZeneca 14,084.00 102.00 0.73% 3.62% Nov/16
Genmab 3,563.00 115.00 3.34% 80.36% Nov/16
Lakefront Biotherapeutics 31.22 1.04 3.45% 17.28% Nov/16
GRIFOLS 11.67 0.02 0.15% 10.23% Nov/16
GlaxoSmithKline 1,938.50 27.00 1.41% 7.72% Nov/16
Hikma Pharmaceutical 1,677.00 42.00 2.57% 6.34% Nov/16
Qiagen NV 45.35 0.05 0.12% 18.88% Nov/16
UCB 297.60 1.10 0.37% 30.18% Nov/16

Indexes Price Day Year Date
BE20 6129 9.02 0.15% 22.06% Nov/16
EU600 665 0.66 0.10% 16.29% Nov/16

argenx SE traded at 881.60 this Monday November 16th, increasing 3.20 or 0.36 percent since the previous trading session. Looking back, over the last four weeks, argenx SE gained 20.80 percent. Over the last 12 months, its price rose by 11.26 percent. Looking ahead, we forecast argenx SE to be priced at 859.60 by the end of this quarter and at 805.59 in one year, according to Trading Economics global macro models projections and analysts expectations.

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.